X4 Pharmaceuticals Inc (XFOR)

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving...

X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving...

Form EFFECT - Notice of Effectiveness

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Form S-3 - Registration statement under Securities Act of 1933

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

- European Commercialization will be Led by X4 Pharmaceuticals’ Partner, Norgine -  - Global, Pivotal Phase 3...

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 - - Positive...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]